Want to see GB:RUA full AI Analyst Report?
Top Page
RUA Life Sciences
(LSE:RUA)
Select Model
Select Model
Rating:55Neutral
Price Target:
29.00 p
▲(1.75% Upside)
Action:Reiterated
Date:08/25/26
The score is driven primarily by mixed fundamentals: strong gross margins and a low-leverage balance sheet, but still-negative operating results and persistently negative cash flow. Technicals are supportive with a clear uptrend, though elevated RSI suggests near-term risk of pullback. Valuation remains constrained by losses (negative P/E), while the corporate update is a positive catalyst due to improving profitability trajectory and the spin-out strategy.
Positive Factors
Revenue scale and strong gross margins
Revenue growth and consistently high gross margins support RUA’s biomaterials and contract manufacturing model. This indicates valuable specialist capabilities and provides operating leverage if customer programs scale further.
Negative Factors
Operating profitability remains unproven
Despite improved results, RUA has not yet demonstrated consistent operating profitability. Continued losses can constrain reinvestment and make the business more dependent on successful execution of its commercial and cost-reduction plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue scale and strong gross margins
Revenue growth and consistently high gross margins support RUA’s biomaterials and contract manufacturing model. This indicates valuable specialist capabilities and provides operating leverage if customer programs scale further.
Read all positive factors
RUA Life Sciences (RUA) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£17.38M
Dividend YieldN/A
Average Volume (3M)128.55K
Price to Earnings (P/E)―
Beta (1Y)0.05
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees59
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding62,060,272
10 Day Avg. Volume142,181
30 Day Avg. Volume128,546
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.98
Price to Sales (P/S)1.57
P/FCF Ratio-23.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£6.89M
RUA Life Sciences Business Overview & Revenue Model
Company Description
RUA Life Sciences plc, operating with its subsidiaries, delivers specialized polymers, various services, and finished products to the global medical device sector, spanning Europe, the United States, and other international markets. The company's ...
How the Company Makes Money
RUA Life Sciences generates revenue primarily by supplying biomaterials and related services to medical device companies and other healthcare manufacturers. Key revenue streams include: (1) Biomaterials sales: selling proprietary or specialized me...
RUA Life Sciences Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
78
Positive
Cash Flow
34
Negative
| Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.46M | 4.11M | 2.19M | 2.18M | 1.63M |
| Gross Profit | 3.06M | 3.17M | 1.72M | 1.43M | 1.04M |
| EBITDA | -383.33K | 401.00K | -1.57M | -1.95M | -2.04M |
| Net Income | -145.33K | 1.00K | -1.44M | -2.00M | -2.07M |
Balance Sheet | |||||
| Total Assets | 9.12M | 9.26M | 8.17M | 5.66M | 7.63M |
| Cash, Cash Equivalents and Short-Term Investments | 3.25M | 3.57M | 3.93M | 1.48M | 2.96M |
| Total Debt | 794.00K | 1.03M | 389.00K | 475.00K | 344.00K |
| Total Liabilities | 1.89M | 1.86M | 987.00K | 980.00K | 1.04M |
| Stockholders Equity | 7.14M | 7.30M | 7.18M | 4.68M | 6.58M |
Cash Flow | |||||
| Free Cash Flow | -298.00K | -281.00K | -1.38M | -1.62M | -3.27M |
| Operating Cash Flow | -137.00K | -219.00K | -1.33M | -1.17M | -2.36M |
| Investing Cash Flow | -59.00K | 70.00K | -85.00K | -449.00K | -904.00K |
| Financing Cash Flow | -459.00K | -196.00K | 3.89M | 132.00K | -66.00K |
RUA Life Sciences Technical Analysis
Positive
28.50
Price Trends
24.22
Positive
22.11
Positive
17.76
Positive
Market Momentum
0.92
Positive
64.74
Neutral
38.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:RUA, the sentiment is Positive. The current price of 28.5 is above the 20-day moving average (MA) of 26.58, above the 50-day MA of 24.22, and above the 200-day MA of 17.76, indicating a bullish trend. The MACD of 0.92 indicates Positive momentum. The RSI at 64.74 is Neutral, neither overbought nor oversold. The STOCH value of 38.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:RUA.
RUA Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | £17.38M | -121.74 | -2.03% | ― | ― | ― | |
55 Neutral | £3.96M | -4.25 | -11.04% | ― | -2.87% | 52.38% | |
53 Neutral | £17.04M | -16.38 | -6.49% | 1.56% | 24.30% | 93.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £57.83M | 10.22 | 9.56% | ― | ― | ― | |
49 Neutral | £22.08M | -1.26 | -1044.57% | ― | 65.60% | 74.84% | |
46 Neutral | £5.94M | -1.52 | -52.92% | ― | 34.02% | -93.85% |
* Healthcare Sector Average
GB:RUA
RUA Life Sciences
28.00
17.00
154.55%
GB:CREO
Creo Medical
12.88
-0.03
-0.19%
GB:GDR
Genedrive
1.38
0.96
227.38%
GB:IHC
Inspiration Healthcare
19.00
-2.50
-11.63%
GB:OPTI
OptiBiotix Health
5.75
-4.50
-43.90%
GB:SUN
Surgical Innovations
0.43
-0.27
-39.29%
RUA Life Sciences Corporate Events
Business Operations and StrategyFinancial Disclosures
RUA Life Sciences Narrows Losses as Core Manufacturing Turns Profitable and Spin-Out Strategy Takes Shape
Positive
Jun 30, 2026
RUA Life Sciences reported interim results for the six months to 31 March 2026 showing a sharp narrowing of losses as it consolidates its shift toward profitable contract manufacturing and biomaterials licensing. Group revenue rose 6.1% to £2...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.